The Zhitong Finance App learned that Hanson Pharmaceuticals (03692) rose more than 5% in the intraday period. As of press release, it had risen 3.71% to HK$33.52, with a turnover of HK$372 million.

According to the news, Hanson Pharmaceuticals announced that the B7-H3 targeting antibody-drug conjugate (ADC) HS-20093, which was independently developed by the company, reached the main end point in a phase III clinical trial (ARTEMIS-011) to treat patients with osteosarcoma that progressed or recurred after receiving at least a second-line system treatment.

Progression-free survival (PFS) assessed by the independent review committee showed statistically significant and clinically significant improvements compared to the chemotherapy group; secondary endpoints such as overall survival (OS) and investigators' evaluation of PFS also showed consistent benefits; safety characteristics were consistent with previous studies, and no new safety signals were found. This achievement lays a key foundation for HS-20093 to submit a new drug marketing application in China. The company will soon begin communication with regulators and advance preparations for the marketing application; detailed data will be announced at future international oncology conferences.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.